Pangaea Oncology S.A. (MC:PANG) — Market Cap & Net Worth
Market Cap & Net Worth: Pangaea Oncology S.A. (PANG)
Pangaea Oncology S.A. (MC:PANG) has a market capitalization of $56.33 Million (€48.18 Million) as of August 1, 2026. Listed on the MC stock exchange, this Spain-based company holds position #21368 globally and #152 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pangaea Oncology S.A.'s stock price €1.55 by its total outstanding shares 34134631 (34.13 Million). Review how much debt does Pangaea Oncology S.A. carry to assess the company's total debt and financial obligations.
Pangaea Oncology S.A. Market Cap History: 2016 to 2026
Pangaea Oncology S.A.'s market capitalization history from 2016 to 2026. Data shows change from $106.46 Million to $61.86 Million (-4.93% CAGR).
Pangaea Oncology S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pangaea Oncology S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.95x
Pangaea Oncology S.A.'s market cap is 4.95 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $106.46 Million | $2.52 Million | -$594.53K | 42.28x | N/A |
| 2017 | $83.04 Million | $2.62 Million | -$1.65 Million | 31.68x | N/A |
| 2018 | $79.89 Million | $3.06 Million | -$1.25 Million | 26.12x | N/A |
| 2019 | $66.86 Million | $3.32 Million | -$4.84 Million | 20.16x | N/A |
| 2020 | $62.93 Million | $4.10 Million | -$1.79 Million | 15.35x | N/A |
| 2021 | $61.74 Million | $4.60 Million | -$641.91K | 13.41x | N/A |
| 2022 | $65.45 Million | $4.37 Million | -$2.71 Million | 14.98x | N/A |
| 2023 | $73.43 Million | $8.00 Million | -$4.66 Million | 9.18x | N/A |
| 2024 | $70.64 Million | $14.27 Million | -$1.17 Million | 4.95x | N/A |
Competitor Companies of PANG by Market Capitalization
Companies near Pangaea Oncology S.A. in the global market cap rankings as of August 1, 2026.
Key companies related to Pangaea Oncology S.A. by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $215.77 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #169 globally with a market cap of $137.72 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #577 globally with a market cap of $46.48 Billion USD ( CN¥317.64 Billion CNY).
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #616 globally with a market cap of $43.83 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $215.77 Billion | $574.30 |
| #169 | Danaher Corporation | NYSE:DHR | $137.72 Billion | $194.98 |
| #577 | WuXi AppTec Co Ltd | SHG:603259 | $46.48 Billion | CN¥128.43 |
| #616 | IDEXX Laboratories Inc | NASDAQ:IDXX | $43.83 Billion | $559.07 |
Pangaea Oncology S.A. Historical Marketcap From 2016 to 2026
Between 2016 and today, Pangaea Oncology S.A.'s market cap moved from $106.46 Million to $ 61.86 Million, with a yearly change of -4.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €61.86 Million | -10.40% |
| 2025 | €69.04 Million | -2.26% |
| 2024 | €70.64 Million | -3.80% |
| 2023 | €73.43 Million | +12.20% |
| 2022 | €65.45 Million | +6.00% |
| 2021 | €61.74 Million | -1.88% |
| 2020 | €62.93 Million | -5.88% |
| 2019 | €66.86 Million | -16.31% |
| 2018 | €79.89 Million | -3.80% |
| 2017 | €83.04 Million | -22.00% |
| 2016 | €106.46 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Pangaea Oncology S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $56.33 Million USD |
| MoneyControl | $56.33 Million USD |
| MarketWatch | $56.33 Million USD |
| marketcap.company | $56.33 Million USD |
| Reuters | $56.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pangaea Oncology S.A.
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vi… Read more